English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, October 16, 2019
エーザイ、抗てんかん剤「フィコンパ(R)」部分てんかん併用療法に係る適応で中国当局より新薬承認を取得
Tuesday, October 15, 2019
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Tuesday, October 1, 2019
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
エーザイ、進行性子宮内膜がんに対する「レンビマ(R)」と「キイトルーダ(R)」との併用療法の最終解析結果を欧州臨床腫瘍学会年次総会において発表
Monday, September 30, 2019
エーザイと日医工、中国におけるジェネリック医薬品事業に関する提携のお知らせ
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Thursday, September 26, 2019
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
エーザイ、入院患者様の転倒・転落予測システム「Coroban(R)」を新発売
エーザイと東京海上日動、認知症との共生と予防の実施にむけて業務提携

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575